skip to main content, skip to Quick links, or skip to Search

main content

Contact Information.

Natasha Olby Vet MB,PhD, MRCVS, DACVIM (Neurology)
Phone: 919-513-8286
Email: natasha_olby@ncsu.edu

Kim Williams
Spinal Cord Injury Program Coordinator
Phone: 919-513-7235
Email: kimberly_williams@ncsu.edu

Back to Canine Spinal Cord Injury Program Home Page

FaceBook

Clinical Trials

A Phase 1 clinical trial of GGF2 in dogs with disc-induced acute spinal cord injuries
Acute spinal cord injuries are a common problem in dogs, and due to the poor regenerative capacity of the nervous system, some dogs fail to recover and are left permanently paralyzed and incontinent. Experimental studies in rodents suggest that Glial Growth Factor 2 (GGF2) improves the recovery from a spinal cord injury. The purpose of this clinical trial is to evaluate the safety of GGF2 in dogs with severe spinal cord injuries due to acute intervertebral disc herniations. For more information..

Methylprednisolone Sodium Succinate and Polyethylene Glycol in Canine Spinal Cord Injury. This is a multicenter trial for dogs that have suffered an acute spinal cord injury due to a disc herniation. Two different neuroprotective drugs are being compared with placebo in surgically treated dogs. To be included in the trial dogs must be paraplegic with no pain sensation in their hind feet, weigh less than 20kg, be aged between 2 and 10 years, and have suffered the injury in the last 24 hours. Sixteen centers across the US are involved in the trial. This trial is funded by Morris Animal Foundation. For more information...

Comparison of the effect of T-BOC, 4-AP and placebo on pelvic limb and bladder function in chronically paraparetic dogs – a blinded study. This trial evaluates two different potassium channel blockers in dogs that are chronically paralyzed due to an acute spinal cord injury. For inclusion in this trial, dogs must be unable to use their hind limbs due to a thoracolumbar spinal cord injury that occurred at least 6 months previously. This trial is funded by NeuroMetrix Inc. For more information...

Treatment of paraparesis in dogs using a novel derivative of 4-aminopyridine. This trial compares the effect of the t-butyl derivative of 4-AP and placebo on hind limb gait in chronically paraparetic dogs. Dogs entering this trial must have chronic neurologic deficits in their pelvic limbs as a result of an acute spinal cord injury at least 6 months previously. They may have some motor function in their hind limbs, but have an obviously abnormal hind limb gait. This trial is funded by Morris Animal Foundation and will start case recruitment in September 2009. For more information...

The Effect of Cranberry Extract on Myelopathy-Associated Urinary Tract Infections in Dogs. Spinal cord injuries affect not only movement of the hind limbs, but also the ability to urinate. While dogs recover from a spinal cord injury they are predisposed to develop urinary tract infections (UTIs) because of a failure to empty their bladder completely. Cranberry extract has been shown to reduce the chance of developing a UTI by preventing certain common types of bacteria from adhering to the bladder wall. In this study we will compare the effect of cranberry extract with placebo on the incidence of UTIs. This study is funded by Morris Animal Foundation. For more information ...

Treatment of Canine Paralysis with Autologous Adipose Tissue Derived Stem Cells, Schwann Cells & Inosine. This trial evaluates the effect of combining transplants of autologous (derived from the patient) Schwann cells (SCs) and Adipose Derived Stromal cells (ADSCs) with an inosine infusion in chronically paralyzed dogs. For inclusion in this trial, dogs must be unable to use their hind limbs due to a thoracolumbar spinal cord injury that occurred at least 3 months previously. This trial is funded by Morris animal Foundation. For more information...